THERAPY DOSSIER · th-159da569f248

Anti-scarring treatment (AST): the iron chelator 2,2'-bipyridine-5,5'-dicarboxylic acid combined with 8-Br-cyclic adenosine monophosphate

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23236355 ↗2012Reported benefit

Age-dependent modulation of cortical transcriptomes in spinal cord injury and repair.

RatSpinal cord injuryHemisection / partialWistar (HanTac:WH)Femalen = 72 female rats (36 young, 36 geriatric) in 18 groups, 4 ani…Local injection into the spinal cord lesion site8 injections of 0.2 microlitres of 40 mM 2,2'-bipyridine-5,…Immediately after hemisection and dural suture

Model: Dorsal spinal cord hemisection including transection of the corticospinal tract with a Scouten wire knife at thoracic level 8 under isoflurane anaesthesia; laminectomy alone as sham

Cortical transcriptomes after spinal cord injury were largely age specific, with only about 7 per cent overlap of lesion-regulated genes between aged and young rats (2488 versus 753 regulated genes). At 35 days post-operation the anti-scarring treatment produced similar profiles in aged and young a…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.88. Machine-extracted fields require source verification.

Loading the evidence…